Latham & Watkins Advises Bioventus in Acquisition of Misonix

Bioventus Inc. (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, have announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.

Latham & Watkins LLP represents Bioventus Inc. in the transaction with a corporate deal team led by Bay Area partner Mark Bekheit and Orange County/New York partner Charles Ruck, with Orange County associates Brett Urig, Stephanie Isaia, and Takeshi Sumida. Advice was also provided on general corporate and securities matters by Boston partner Wesley Holmes, with New York associate Katie Lovejoy; on public company matters by New York partner Dennis Craythorn, with New York associate Katie Marren; on tax matters by Washington, D.C. partner Andrea Ramezan-Jackson, with Washington, D.C. associate Eli McCrain; on debt matters by New York partner Abhay Lele, with New York associate Michael Waldman; on employee benefits matters by New York counsel Rifka Singer, with Chicago associate Daniel Gocek; on intellectual property matters by Bay Area partner Judith Hasko, with Boston associate Seth Appiah-Opoku; on data privacy matters by Washington, D.C. counsel Marissa Boynton, with Washington, D.C. associate James Smith; on FDA regulatory matters by Washington, D.C. partner Elizabeth Richards, with Washington, D.C. associate Seth Olson; on healthcare regulatory matters by Washington, D.C. counsel Nicole Liffrig Molife, with Washington, D.C. associates Alyssa Lattner and Maria Malas; and on antitrust matters by Washington, D.C. partner Many Reeves, Brussels partner Héctor Armengod, and Washington, D.C. counsel Patrick English, with Brussels associate Apostolos Papadimitriou.